Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rifaximin vs Low FODMAP Diet in IBS
NCT04841980Phase 4Unknown
- Sponsor
- Universiti Malaya
- Start
- Apr 2021
- Primary completion
- May 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of rifaximin in irritable bowel syndrome (IBS), small intestinal bacterial overgrowth (SIBO), sponsored by Universiti Malaya. Status: unknown.
02
Drugs
rifaximin
03
Conditions
irritable bowel syndrome (IBS)small intestinal bacterial overgrowth (SIBO)
Beyond the preview
Go deeper on NCT04841980.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04841980.